Hsc clinical trials controversy continues

Access through your institution Buy or subscribe _To the editor_—We write to correct inaccuracies in your October issue editorial and news article concerning the controversial clinical trial

involving Nancy Olivieri, The Hospital for Sick Children (HSC) and Apotex Inc. Whereas there is no question that this case is complicated and that there are as many interpretations of the

facts as there are involved parties, the allegation that the HSC administration "completely failed to support the efforts of Olivieri" is false and the implication that we did not

support Olivieri's right to publish is unwarranted. In a letter dated 24 May 1996, Apotex notified Olivieri (and her collaborator Gideon Koren) that they would not renew the contract

supporting the trial of L–1 (Deferiprone). Apotex also warned Olivieri and Koren that they would pursue legal remedies if they breached the obligations in their previous three–year contract.

In a letter dated 25 May, Olivieri and Koren informed the hospital that they had already sought legal counsel, who had advised them to contact the Canadian Medical Protective Association

(CMPA). When Olivieri subsequently met with university officials on 6 June, and with hospital representatives on 18 July, she was represented by a lawyer from McCarthy Tetrault, the firm

retained by the CMPA. It was not until the hospital board of directors initiated an independent external review that Olivieri requested legal assistance from the hospital in this matter.

Olivieri has been continuously represented by lawyers from McCarthy Tetrault. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your

institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access

to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read

our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Director, The Hospital for Sick Children Research Institute, Chief of Research, The Hospital for Sick

Children, Molecular and Medical Genetics, University of Toronto,, Manuel Buchwald * Chief of Paediatrics, The Hospital for Sick Children, Chairman of Paediatrics, Faculty of Medicine,

University of Toronto, Hugh O'Brodovich Authors * Manuel Buchwald View author publications You can also search for this author inPubMed Google Scholar * Hugh O'Brodovich View

author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Buchwald, M.,

O'Brodovich, H. HSC clinical trials controversy continues. _Nat Med_ 5, 2 (1999). https://doi.org/10.1038/4667 Download citation * Issue Date: January 1999 * DOI:

https://doi.org/10.1038/4667 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently

available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative